Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports

Purchase Licensing Rights Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Logos of Gilead at the company's booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab March 23 (Reuters) - Gilead Sciences (GILD.O), opens new tabis nearing an acquisition of biot ...